

NEUROENDOCRINE TUMOR STAGING FORM

CLINICAL <i>Extent of disease before any treatment</i>	STAGE CATEGORY DEFINITIONS	PATHOLOGIC <i>Extent of disease through completion of definitive surgery</i>
<input type="checkbox"/> y clinical— staging completed after neoadjuvant therapy but before subsequent surgery	TUMOR SIZE: _____	<input type="checkbox"/> y pathologic – staging completed after neoadjuvant therapy AND subsequent surgery
<div style="display: flex; justify-content: space-between;"> <div style="width: 15%;"> <input type="checkbox"/> TX <input type="checkbox"/> T0 <input type="checkbox"/> Tis <input type="checkbox"/> T1 <input type="checkbox"/> T2 <input type="checkbox"/> T3 <input type="checkbox"/> T4 </div> <div style="width: 80%;"> <p style="text-align: center;">PRIMARY TUMOR (T)</p> <p><i>Stomach</i> Primary tumor cannot be assessed No evidence of primary tumor Carcinoma <i>in situ</i>/dysplasia (tumor size <0.5mm), confined to mucosa Tumor invades lamina propria or submucosa and ≤1cm in size Tumor invades muscularis propria or >1cm in size Tumor penetrates subserosa Tumor invades visceral peritoneum (serosa) or other organs or adjacent structures For any T, add (m) for multiple tumors</p> <p><i>Duodenum/Ampulla/Jejunum/Ileum</i> Primary tumor cannot be assessed No evidence of primary tumor Tumor invades lamina propria or submucosa and size ≤1 cm (small intestinal tumors); tumor ≤1 cm (ampullary tumors) Tumor invades muscularis propria or size >1 cm (small intestinal tumors); tumor >1 cm (ampullary tumors) Tumor invades through the muscularis propria into subserosal tissue without penetration of overlying serosa (jejunal or ileal tumors) or invades pancreas or retroperitoneum (ampullary or duodenal tumors) or into non-peritonealized tissues. Tumor invades visceral peritoneum (serosa) or invades other organs For any T, add (m) for multiple tumors *Tumor limited to ampulla of Vater for ampullary gangliocytic paraganglioma</p> <p><i>Colon or Rectum</i> Primary tumor cannot be assessed No evidence of primary tumor Tumor invades lamina propria or submucosa and size ≤2 cm Tumor size <1 cm in greatest dimension Tumor size 1 to 2 cm in greatest dimension Tumor invades muscularis propria or size >2 cm with invasion of lamina propria or submucosa Tumor invades through the muscularis propria into the subserosa, or into non-peritonealized pericolic or perirectal tissues Tumor invades peritoneum or other organs For any T, add (m) for multiple tumors</p> </div> </div>	<div style="display: flex; justify-content: space-between;"> <div style="width: 15%;"> <input type="checkbox"/> TX <input type="checkbox"/> T0 <input type="checkbox"/> Tis <input type="checkbox"/> T1 <input type="checkbox"/> T2 <input type="checkbox"/> T3 <input type="checkbox"/> T4 </div> <div style="width: 80%;"></div> </div>	
<div style="display: flex; justify-content: space-between;"> <div style="width: 15%;"> <input type="checkbox"/> NX <input type="checkbox"/> N0 <input type="checkbox"/> N1 </div> <div style="width: 80%;"> <p style="text-align: center;">REGIONAL LYMPH NODES (N)</p> <p><i>Stomach</i> Regional lymph nodes cannot be assessed No regional lymph node metastasis Regional lymph node metastasis</p> </div> </div>	<div style="display: flex; justify-content: space-between;"> <div style="width: 15%;"> <input type="checkbox"/> NX <input type="checkbox"/> N0 <input type="checkbox"/> N1 </div> <div style="width: 80%;"></div> </div>	
HOSPITAL NAME/ADDRESS		PATIENT NAME/INFORMATION

(continued on next page)

NEUROENDOCRINE TUMOR STAGING FORM

<input type="checkbox"/> NX <input type="checkbox"/> N0 <input type="checkbox"/> N1 <input type="checkbox"/> NX <input type="checkbox"/> N0 <input type="checkbox"/> N1	Duodenum/Ampulla/Jejunum/Ileum Regional lymph nodes cannot be assessed No regional lymph node metastasis Regional lymph node metastasis Colon or Rectum Regional lymph nodes cannot be assessed No regional lymph node metastasis Regional lymph node metastasis	<input type="checkbox"/> NX <input type="checkbox"/> N0 <input type="checkbox"/> N1 <input type="checkbox"/> NX <input type="checkbox"/> N0 <input type="checkbox"/> N1
DISTANT METASTASIS (M)		
<input type="checkbox"/> M0 <input type="checkbox"/> M1 <input type="checkbox"/> M0 <input type="checkbox"/> M1 <input type="checkbox"/> M0 <input type="checkbox"/> M1	Stomach No distant metastasis (no pathologic M0; use clinical M to complete stage group) Distant metastasis Duodenum/Ampulla/Jejunum/Ileum No distant metastasis (no pathologic M0; use clinical M to complete stage group) Distant metastasis Colon or Rectum No distant metastasis (no pathologic M0; use clinical M to complete stage group) Distant metastasis	<input type="checkbox"/> M1 <input type="checkbox"/> M1 <input type="checkbox"/> M1

ANATOMIC STAGE • PROGNOSTIC GROUPS							
CLINICAL				PATHOLOGIC			
GROUP	T	N	M	GROUP	T	N	M
<input type="checkbox"/> 0	Tis*	N0	M0	<input type="checkbox"/> 0	Tis*	N0	M0
<input type="checkbox"/> I	T1	N0	M0	<input type="checkbox"/> I	T1	N0	M0
<input type="checkbox"/> IIA	T2	N0	M0	<input type="checkbox"/> IIA	T2	N0	M0
<input type="checkbox"/> IIB	T3	N0	M0	<input type="checkbox"/> IIB	T3	N0	M0
<input type="checkbox"/> IIIA	T4	N0	M0	<input type="checkbox"/> IIIA	T4	N0	M0
<input type="checkbox"/> IIIB	Any T	N1	M0	<input type="checkbox"/> IIIB	Any T	N1	M0
<input type="checkbox"/> IV	Any T	Any N	M1	<input type="checkbox"/> IV	Any T	Any N	M1
<input type="checkbox"/> Stage unknown <i>*Note: Tis applies only to stomach.</i>				<input type="checkbox"/> Stage unknown <i>*Note: Tis applies only to stomach.</i>			

PROGNOSTIC FACTORS (SITE-SPECIFIC FACTORS)									
REQUIRED FOR STAGING: None CLINICALLY SIGNIFICANT: Pre-operative plasma chromogranin A level (CgA) _____ Urinary 5-hydroxyindolacetic acid (5-HIAA) level _____ Mitotic count _____	General Notes: For identification of special cases of TNM or pTNM classifications, the "m" suffix and "y," "r," and "a" prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis. m suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM. y prefix indicates those cases in which classification is performed during or following initial multimodality therapy. The cTNM or pTNM category is identified by a "y" prefix.								
Histologic Grade (G) (also known as overall grade) <table style="width: 100%;"> <tr> <th style="text-align: left;">Grading system</th> <th style="text-align: left;">Grade</th> </tr> <tr> <td><input type="checkbox"/> 2 grade system</td> <td><input type="checkbox"/> Grade I or 1</td> </tr> <tr> <td><input type="checkbox"/> 3 grade system</td> <td><input type="checkbox"/> Grade II or 2</td> </tr> <tr> <td><input type="checkbox"/> No 2 or 3 grade system is available</td> <td><input type="checkbox"/> Grade III or 3</td> </tr> </table>		Grading system	Grade	<input type="checkbox"/> 2 grade system	<input type="checkbox"/> Grade I or 1	<input type="checkbox"/> 3 grade system	<input type="checkbox"/> Grade II or 2	<input type="checkbox"/> No 2 or 3 grade system is available	<input type="checkbox"/> Grade III or 3
Grading system	Grade								
<input type="checkbox"/> 2 grade system	<input type="checkbox"/> Grade I or 1								
<input type="checkbox"/> 3 grade system	<input type="checkbox"/> Grade II or 2								
<input type="checkbox"/> No 2 or 3 grade system is available	<input type="checkbox"/> Grade III or 3								

HOSPITAL NAME/ADDRESS	PATIENT NAME/INFORMATION
-----------------------	--------------------------

(continued from previous page)

NEUROENDOCRINE TUMOR STAGING FORM

ADDITIONAL DESCRIPTORS

Lymphatic Vessel Invasion (L) and Venous Invasion (V) have been combined into Lymph-Vascular Invasion (LVI) for collection by cancer registrars. The College of American Pathologists' (CAP) Checklist should be used as the primary source. Other sources may be used in the absence of a Checklist. Priority is given to positive results.

- ☐ Lymph-Vascular Invasion Not Present (absent)/Not Identified
- ☐ Lymph-Vascular Invasion Present/Identified
- ☐ Not Applicable
- ☐ Unknown/Indeterminate

Residual Tumor (R)

The absence or presence of residual tumor after treatment. In some cases treated with surgery and/or with neoadjuvant therapy there will be residual tumor at the primary site after treatment because of incomplete resection or local and regional disease that extends beyond the limit of ability of resection.

- ☐ RX Presence of residual tumor cannot be assessed
- ☐ R0 No residual tumor
- ☐ R1 Microscopic residual tumor
- ☐ R2 Macroscopic residual tumor

General Notes (continued):

The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The "y" categorization is not an estimate of tumor prior to multimodality therapy.

r prefix indicates a recurrent tumor when staged after a disease-free interval, and is identified by the "r" prefix: rTNM.

a prefix designates the stage determined at autopsy: aTNM.

surgical margins is data field recorded by registrars describing the surgical margins of the resected primary site specimen as determined only by the pathology report.

neoadjuvant treatment is radiation therapy or systemic therapy (consisting of chemotherapy, hormone therapy, or immunotherapy) administered prior to a definitive surgical procedure. If the surgical procedure is not performed, the administered therapy no longer meets the definition of neoadjuvant therapy.

☐ Clinical stage was used in treatment planning (describe): _____

☐ National guidelines were used in treatment planning ☐ NCCN ☐ Other (describe): _____

Physician signature

Date/Time

HOSPITAL NAME/ADDRESS

PATIENT NAME/INFORMATION